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Abstract Q-Glutamyl semialdehyde is a primary oxidation
product of apolipoprotein (apo) B-100 proline (Pro) and arginine
(Arg) side chain residues. By reduction Q-glutamyl semialdehyde
forms 5-hydroxy-2-aminovaleric acid (HAVA). Here we describe
the application of sensitive and specific HAVA measurement to
characterize the formation of Q-glutamyl semialdehyde in several
domains of apoB-100 in LDL1 (Sf 7^12) and LDL2 (Sf 0^7)
subfractions subjected to oxidative damage in the presence of
iron in vitro. Results suggest that susceptibility of apoB-100 Pro
and Arg residues toward oxygen radicals drastically changes
along the lipoprotein metabolic cascade. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Oxidative modi¢cation of low density lipoprotein (LDL)
apolipoprotein B-100 (apoB-100) by reactive oxygen species
is regarded as a crucial event in atherogenesis [1,2]. ApoB-100
modi¢cation, e.g. binding of lipid peroxidation products or
direct oxidation of amino acid side chain residues, is thought
to ¢nally result in the formation of new epitopes that are
speci¢cally recognized by scavenger receptors [2^5]. However,
the nature of such new epitopes is still a matter of debate [6,7].
Recently, the oxidation of LDL apoB-100 Pro and Arg resi-
dues primarily to Q-glutamyl semialdehyde, which by reduc-
tion forms 5-hydroxy-2-aminovaleric acid (HAVA), has been
measured in vitro and in circulating LDL in vivo [8,9]. Studies
in normolipidemic and hypercholesterolemic subjects revealed
that an entity of small, more dense, K-tocopherol-poor LDL
particles (LDL2, Svedberg units (Sf ) 0^7) is particularly prone
to direct apoB-100 oxidation in vivo [9]. The longer the resi-
dence time of these particles the more Pro and Arg residues of
apoB-100 become modi¢ed [9]. These studies lead to the hy-
pothesis that an alteration of apoB-100 conformation during
the conversion of large, buoyant LDL1 to small, more dense
LDL2 particles along the lipoprotein metabolic cascade
should contribute to increased accessibility of apoB-100 to-
ward oxidative modi¢cation. To prove this hypothesis, the
present study uses speci¢c and sensitive gas chromatogra-
phy-mass spectrometry (GC-MS) methodology to measure
HAVA formation in di¡erent domains of apoB-100 of
LDL1 (Sf 7^12) and LDL2 (Sf 0^7) subjected to oxidative
damage in the presence of iron in vitro.
2. Materials and methods
2.1. Chemicals
Ethyl chloroformate was obtained from Fluka (Buchs, Switzer-
land). Human thrombin (2910 NIH U/mg protein), protein L-amino
acids, L-norleucine (internal standard), bovine hemin chloride, and
non-speci¢c protease type XIV (from Streptomyces griseus) were pur-
chased from Sigma (St. Louis, MO, USA). All other reagents were
purchased from Sigma and Bio-Rad (Richmond, CA, USA).
2.2. Isolation and in vitro oxidation of human LDL subfractions
Blood samples were obtained from 10 healthy, normolipidemic
male volunteers (23^28 years old) after overnight fasting and collected
into polypropylene tubes containing EDTA at a ¢nal concentration of
0.1%. The blood was centrifuged at 4‡C (2000Ug for 10 min) to
separate cells from plasma. Blood plasma and LDL were all processed
in subdued light to prevent the photooxidation of LDL. All bu¡ers
and solutions were degassed and stored under argon. Buoyant LDL1
(Sf 7^12) and small, dense LDL2 (Sf 0^7) were isolated from plasma
by a combination of both cumulative and sequential density gradient
ultracentrifugation techniques as previously described [10,11]. LDL
apoB-100 was measured by immunoelectrophoresis using ‘ready-to-
use’ agarose gels (Sebia, Issy-les-Moulineaux, France). Total LDL
cholesterol was determined enzymatically using CHOD-PAP test
kits (Roche, Mannheim, Germany). LDL K-tocopherol content was
measured by high-performance liquid chromatography as described
elsewhere and is expressed as mol/mol apoB-100 [12]. Immediately
before oxidation of LDL. EDTA and salt from the density gradient
were removed using a size exclusion column (Econo-Pac 10DG, Bio-
Rad) and 10 mM Tris, 0.01% NaN3, pH 8.0, as the eluent. For
oxidation, aliquots of native LDL1 and LDL2 (100 Wg apoB-100/ml)
were incubated with hemin/H2O2 (1 WM bovine hemin chloride and 10
WM H2O2) at 37‡C for 40 h in the dark [8,13]. LDL samples of 1 ml
were withdrawn from the oxidation system immediately before adding
the oxidants (time 0 h) and at various time points during oxidation.
2.3. Digestion of LDL apoB-100 with thrombin and separation of
thrombolytic peptides
The method of Cardin and coworkers was used to digest apoB-100
of LDL1 and LDL2 with thrombin [14]. In brief, after oxidation
aliquots of LDL1 and LDL2 samples (0.5 ml) were incubated with
5 Wg of thrombin (100 Wg/ml) at 25‡C for 3 h. Undigested and di-
gested LDL samples were transferred into vials containing 2 ml of an
ice-cold chloroform:methanol mixture (2:1, v/v). After vortexing and
centrifugation (4000Ug, 4‡C, 10 min) the bottom chloroform layer
was removed and discarded. The extraction was repeated three times.
In the remaining aqueous phase most of precipitated apoB-100 and
apoB-100 digestion products, respectively, were pelleted. The tubes
were placed in an exsiccator and residual chloroform was removed
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by the vacuum of a water suction pump (20 min). Thereafter, the
tubes were transferred to a freeze dryer and the aqueous phase was
evaporated. The formation of HAVA requires the reduction of the
polypeptides with sodium borohydride [8,15]. Therefore, to the resi-
due a volume of 10 Wl 1 M Tris^HCl (pH 8.5), 100 Wl water, and 30 Wl
of 0.1 M sodium borohydride in 0.1 N NaOH was added and the
tubes were vortexed. After incubation at 37‡C for 30 min, 1 ml of 10%
trichloroacetic acid (TCA) was added. Samples were centrifuged and
washed twice with 10% TCA. Samples containing undigested apoB-
100 were dried again and 2 ml water was added. Digested LDL sam-
ples were incubated for 30 min at 95‡C in 200 Wl of bu¡er (8% SDS,
5 mM EDTA, 0.25 M boric acid, 40 mM dithiothreitol, and 0.005%
bromophenol blue in 10 mM Tris; pH 6.8). Thrombolytic fragments
of both LDL1 and LDL2 apoB-100 were then separated by prepara-
tive SDS^PAGE (5^15%) using a Tris-glycine bu¡er system [16]. The
gels were stained with Coomassie brilliant blue R250 to visualize the
apoB-100 digestion products and scanned in an integrating densitom-
eter to estimate pool sizes of thrombolytic fragments. Immunoblotting
(touch blotting) served for de¢nite identi¢cation of apolipoproteins
[11]. The stained bands were excised, homogenized and 2 ml water
was added. Then, to each tube (digested and undigested samples) 0.3
ml of bacterial protease type XIV solution (3.8 mg/ml in phosphate-
bu¡ered saline, pH 7.4) was added and the tubes were covered with
para¢lm. The mixture was incubated in the dark at 37‡C for 24 h.
Thereafter, the tubes were frozen and freeze-dried.
2.4. Determination of HAVA
The free amino acids were isolated from apoB-100 or thrombolytic
fragment hydrolysates, derivatized to their N(O)-ethoxycarbonyl ethyl
ester derivatives, and analyzed by electron-impact ionization GC-MS
following the protocol as described elsewhere [8]. HAVA content in
all samples is expressed as mol/mol apoB-100 (intraassay CV,
6 4.5%; interassay CV, 6 6.1%). A shortcoming of this GC-MS
method is the inability to directly determine Arg, owing to the under-
ivatized imino group of the guanidine moiety of Arg that is not eluted
under the conditions employed. Therefore, for the present study the
loss of apoB-100 Arg side chain residues during iron-catalyzed oxida-
tion was determined by derivatization to N(O)-hepta£uorobutyryl iso-
butyl esters and GC-methane-negative ion chemical ionization MS as
previously published [11].
2.5. Statistical analysis
Descriptive data were expressed as arithmetic means þ S.D. Statis-
tical analyses (Mann^Whitney tests) were calculated using the SPSS
9.0 software package.
3. Results
For the present study large, buoyant LDL1 (total cholester-
ol, 2.37 þ 0.34 mM; apoB-100, 0.59 þ 0.11 g/l ; K-tocopherol,
5.14 þ 1.47 mol/mol apoB-100) and small, more dense LDL2
(0.38 þ 0.09 mM, P6 0.01; 0.12 þ 0.02 g/l, P6 0.01;
1.34 þ 0.32 mol/mol apoB-100, P6 0.01) from 10 normolipid-
emic donors were subjected to iron-catalyzed oxidation using
hemin/H2O2 in vitro. To investigate the time course of the
conversion of Pro and Arg side chain residues in apoB-100
to Q-glutamyl semialdehyde during oxidation of LDL subfrac-
tions, HAVA levels were measured at di¡erent time points
(Fig. 1). HAVA content in LDL1 apoB-100 increased within
40 h from an initial value of 0.005 þ 0.001 to 13.95 þ 0.91 mol/
mol apoB-100 and in LDL2 apoB-100 from 0.020 þ 0.003 to
20.37 þ 1.05 mol/mol apoB-100, respectively. For native LDL
(t = 0 h) the HAVA content in LDL2 was higher when com-
pared with LDL1 (0.62:10 000 vs. 0.16:10 000 Pro/Arg;
P6 0.01). Furthermore, the initial slope and the extent of
HAVA formation during oxidation were signi¢cantly higher
in LDL2 apoB-100 when compared with LDL1 (Fig. 1). In
parallel, the loss of apoB-100 Pro and Arg side chain residues
was measured during oxidation of LDL subfractions. Pro res-
idues in LDL1 apoB-100 decreased within 40 h from 170 þ 3
to 158 þ 4 mol/mol apoB-100 (P6 0.05) and in LDL2 apoB-
100 from 170 þ 3 to 156 þ 3 mol/mol apoB-100 (P6 0.05),
respectively. Arg residues in LDL1 apoB-100 decreased from
148 þ 3 to 140 þ 2 mol/mol apoB-100 (P6 0.05) and in LDL2
apoB-100 from 148 þ 3 to 131 þ 3 mol/mol apoB-100
(P6 0.01), respectively. To further explore the distribution
of modi¢ed Pro and Arg residues along the apoB-100 mole-
cule, the approach of limited proteolysis with thrombin was
used to break oxidized apoB-100 of LDL subfractions into
de¢nite fragments [14,17]. The mature apoB-100 is a large
protein consisting of a single polypeptide chain of 4536 amino
acids, and there is one copy of the protein on each LDL
particle. ApoB-100 has a molecular weight (Mr) of
W550 000 (with carbohydrate content), and contains 170 pro-
line residues and 148 arginine residues [17]. Under the proteo-
lytic conditions employed apoB-100 cleavage of both LDL1
and LDL2 particles gives the two fragments T1 and T2, cor-
responding to residues 1^3249 (MrW380 000) and 3250^4536
(MrW170 000) of the apoB-100 molecule, respectively [14].
Only trace amounts (6 3% of total apoB-100 mass) of T3
and T4 fragments, corresponding to residues 1298^3249 and
1^1297, have been found that were not subjected to further
analysis. A fragmentation of apoB-100 only due to hemin-
mediated oxidation of LDL before thrombin cleavage of
apoB-100 has not been observed [18].
In LDL1-T1 the HAVA content increased within 40 h from
an initial value of 0.002 þ 0.001 to 9.88 þ 0.74 mol/mol apoB-
100 and in LDL1-T2 from 0.002 þ 0.001 to 3.64 þ 0.31 mol/mol
apoB-100, respectively. In LDL2-T1 the HAVA content in-
creased within 40 h from an initial value of 0.013 þ 0.004 to
12.24 þ 0.91 mol/mol apoB-100 and in LDL2-T2 from
0.005 þ 0.001 to 7.01 þ 0.52 mol/mol apoB-100, respectively
(Figs. 2 and 3). The mean recovery of HAVA in T1 and T2
fragments of LDL subfractions compared to undigested
apoB-100 was 95.2 þ 3.2%. For both T1 and T2 fragments
the slope and the extent of HAVA formation in LDL2 were
signi¢cantly higher when compared with LDL1 (Figs. 2 and
3).
From the apoB-100 amino acid sequence of Knott and co-
Fig. 1. Kinetics of formation of HAVA in LDL1 (squares) and
LDL2 (triangles) apoB-100 oxidized by hemin/H2O2. Data are
means þ S.D. of 10 di¡erent samples. Asterisks indicate statistical
di¡erence between LDL subfractions during oxidation (P6 0.01,
Mann^Whitney test). Initial di¡erences (t = 0 h) are given in Section
3.
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workers, the total number of Pro and Arg residues in T1 and
T2 is 234 (73.6% of total Pro/Arg) and 84 (26.4%), respectively
[17]. Pro and Arg residues are distributed in a similar ratio in
T1 (Pro:Arg = 1.13) and T2 (1.21). For both LDL1 and LDL2,
the increment in HAVA formation in T1 fragments was sig-
ni¢cantly higher when compared with T2 fragments (Figs. 2
and 3). On the assumption that apoB-100 is completely
cleaved by thrombin into T1 and T2 fragments and HAVA,
Pro, and Arg were completely released from digestion prod-
ucts by enzymatic hydrolysis, respectively, and considering a
mean recovery of 95%, after 40 h LDL1-T1 contained 72.9%
and LDL1-T2 contained 27.1% of total HAVA formed. This is
nearly proportional to the occurrence of Pro/Arg residues in
each fragment. Of note, in LDL2 the distribution of HAVA
lost this proportionality and signi¢cantly changed to 64.7% in
LDL2-T1 and 35.3% in LDL2-T2 (P6 0.05), respectively.
4. Discussion
Oxidation of LDL apoB-100 in the presence of iron as an
oxidant is an experimental model that may have pathophysi-
ological relevance [19,20]. Apparently, redox-active transition
metals (e.g. Fe2/Fe3) bind to discrete metal binding sites of
apoB-100 and form centers for repeated radical production.
The exact number of such binding sites is not known, and
values ranging from three to about 12 have been reported
by others [5,21,22]. Q-Glutamyl semialdehyde is a primary
product of iron-mediated oxidation of both Pro and Arg
side chain residues and may arise directly via oxidation of
the former, or via initial hydrogen abstraction at carbon six,
and subsequent loss of the guanidine group of Arg in the
presence of oxygen [15,23,24]. By reduction with sodium bo-
rohydride, Q-glutamyl semialdehyde forms HAVA that re-
cently has been shown to be a speci¢c marker for human
LDL apoB-100 oxidation in vitro and in vivo [8,9,15].
The present work ¢rst reports on experiments using HAVA
measurement and limited proteolysis of apoB-100 to further
understand di¡erences in accessibility of de¢nite domains of
apoB-100 of human LDL subfractions to oxidative attack.
The data indicate that during the metabolic conversion of
LDL particles from large, buoyant LDL1 into small, more
dense LDL2 the susceptibility of apoB-100 to iron-catalyzed
oxidation clearly increases. As lipoprotein kinetic studies sup-
posed the majority of LDL1 is a precursor of LDL2. During
intravascular processing by concerted action of lipoprotein
and hepatic lipases, lipid transfer proteins, and receptor-medi-
ated clearance the large, buoyant LDL1 particles become
smaller and more dense [11,25]. This process is accompanied
by changes in LDL particle composition and apoB-100 con-
formation [21,26]. In normolipidemic subjects LDL2 contains
less cholesterol and K-tocopherol molecules per particle than
LDL1. Cholesterol-depleted LDL2 has been shown to be more
prone toward lipid peroxidation in vitro than LDL1 [21]. In
these studies, only the amount of free cholesterol per particle
was associated with LDL oxidizability [21]. Recently, an in
vivo study in subjects with normolipidemic and hypercholes-
terolemic subjects showed lower LDL K-tocopherol content to
be weakly associated with a higher degree of apoB-100 oxida-
tion in LDL2 [9]. Under hypertriglyceridemic conditions, pool
sizes of small, dense LDL increase, and additionally, the par-
ticles become enriched in triglycerides and free fatty acids.
The latter also is supposed to favor the susceptibility of
LDL2 toward lipid peroxidation [26]. Furthermore, compared
to large LDL1, small, more dense LDL2 particles have a dif-
ferent apoB-100 overall structure [26,27].
In this context, the present data showed Pro/Arg side chain
residues in LDL2 apoB-100 to be more sensitive to form Q-
glutamyl semialdehyde and HAVA, respectively, than in
LDL1 apoB-100. In LDL2, there seems to exist a preference
for modi¢cation of Arg when compared with LDL1. In addi-
tion, the domain of apoB-100 covered by the T2 fragment
becomes to a signi¢cantly higher extent susceptible to oxida-
tion during metabolic conversion of LDL when compared
with T1. The latter clearly indicates that changes in three-
dimensional structure and folding of apoB-100 within the
lipoprotein particles during their metabolic conversion con-
tribute to the accessibility of apoB-100 to oxidative attack.
Both T1 and T2 fragments contain Pro-rich clusters and
Arg-rich stretches of basic residues that are supposed to be
involved in receptor binding of LDL [17,28,29]. Furthermore,
Fig. 2. Kinetics of formation of HAVA in LDL1-T1 (squares) and
LDL2-T1 (triangles). Data are means þ S.D. of 10 di¡erent samples.
Asterisks indicate statistical di¡erence between LDL subfractions
during oxidation (P6 0.01, Mann^Whitney test).
Fig. 3. Kinetics of formation of HAVA in LDL1-T2 (squares) and
LDL2-T2 (triangles). Data are means þ S.D. of 10 di¡erent samples.
Asterisks indicate statistical di¡erence between LDL subfractions
during oxidation (P6 0.01, Mann^Whitney test).
FEBS 24627 19-2-01
J. Pietzsch, U. Julius/FEBS Letters 491 (2001) 123^126 125
the T2 fragments comprise the putative LDL receptor binding
region (residues 3373^3393) that alone contains three Arg
residues [17,28,29]. Thus, a higher extent of oxidative Pro/
Arg modi¢cation in small, more dense LDL2, and particu-
larly, in the T2 fragment, is suggested to have consequences
for the metabolic fate of these lipoprotein particles. In con-
clusion, the present experimental ¢ndings support former ¢nd-
ings on pronounced LDL2 oxidation in hyperlipidemic sub-
jects in vivo and provide further explanation for increased
atherogenicity of small, more dense LDL particles. The ex-
periments support the hypothesis that a pathway involving a
ferric/ferryl cycle of the heme iron and hydroperoxides may be
of pathological signi¢cance [19,30]. However, additional work
is needed to understand the speci¢c consequences of Q-glutam-
yl semialdehyde formation for the metabolic fate of apoB-
containing lipoproteins in vivo.
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